The authors also found that high levels of pre-operative CD26(+) cells predicted tumor recurrence (44.4% of patients with high CD26(+) cell counts had recurrence, while only 5% of patients with normal CD26(+) cell counts had recurrence). This evidence concerns the gene DPP4 and neoplasm.